Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cp 529,414
2. Cp 529414
3. Cp-529,414
4. Cp-529414
5. Cp529,414
6. Cp529414
1. 262352-17-0
2. Cp-529414
3. Cp 529414
4. Cp-529,414
5. (2r,4s)-4-((3,5-bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
6. Chembl479527
7. Ethyl (2r,4s)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
8. Ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate
9. Ethyl (2r,4s)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
10. Chebi:49203
11. 4n4457mv2u
12. Torcetrapib [usan]
13. 1(2h)-quinolinecarboxylic Acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
14. (2r,4s)-ethyl 4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
15. (2r,4s)-rel-ethyl 4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h)-carboxylate
16. 262350-59-4
17. Torcetrapib (usan/inn)
18. Torcetrapib [usan:inn]
19. Unii-4n4457mv2u
20. Torcetrapib [mi]
21. Torcetrapib [inn]
22. Torcetrapib [mart.]
23. Schembl49081
24. Torcetrapib [who-dd]
25. Mls006010664
26. Torcetrapib (cp-529414)
27. Torcetrapib, >=98% (hplc)
28. Dtxsid20180873
29. Ex-a081
30. Amy24146
31. Zinc8214714
32. Bdbm50312718
33. Mfcd09260777
34. S2792
35. Akos024458018
36. Ccg-270197
37. Cs-3497
38. Db06281
39. Ncgc00346703-01
40. Ncgc00346703-03
41. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl) (methoxycarbonyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
42. Ac-35371
43. As-16356
44. Ethyl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonyl-amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate
45. Hy-12089
46. Smr004701649
47. D06195
48. A818334
49. Sr-01000944945
50. Q7825530
51. Sr-01000944945-1
52. W-202112
53. Brd-k55675242-001-03-0
54. (2r, 4s)-4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2h-quinoline-1-carboxylic Acid Ethyl Ester
55. (2r,4s)-4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-1-carboxylic Acid Ethyl Ester
56. (2r,4s)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2h
57. 0rp
58. 1(2h)-quinolinecarboxylic Acid, 4-(((3,5-bis(trifluoromethyl)phenyl)methyl) (methoxycarbonyl)amino)-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, Ethyl Ester, (2r,4s)-
Molecular Weight | 600.5 g/mol |
---|---|
Molecular Formula | C26H25F9N2O4 |
XLogP3 | 7 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 7 |
Exact Mass | 600.16706074 g/mol |
Monoisotopic Mass | 600.16706074 g/mol |
Topological Polar Surface Area | 59.1 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 889 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in peripheral vascular disease and hyperlipidemia.
Anticholesteremic Agents
Substances used to lower plasma cholesterol levels. (See all compounds classified as Anticholesteremic Agents.)
Torcetrapib is an inhibitor of cholesteryl ester-transfer protein (CETP) that increases high-density lipoprotein (HDL) cholesterol levels. The drug increases HDL-cholesterol and apolipoprotein A-I levels and decreases LDL-cholesterol and apolipoprotein B levels. The effect is showed in monotherapy and when administered in combination with statins.
ABOUT THIS PAGE
A Torcetrapib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Torcetrapib, including repackagers and relabelers. The FDA regulates Torcetrapib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Torcetrapib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Torcetrapib supplier is an individual or a company that provides Torcetrapib active pharmaceutical ingredient (API) or Torcetrapib finished formulations upon request. The Torcetrapib suppliers may include Torcetrapib API manufacturers, exporters, distributors and traders.
Torcetrapib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Torcetrapib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Torcetrapib GMP manufacturer or Torcetrapib GMP API supplier for your needs.
A Torcetrapib CoA (Certificate of Analysis) is a formal document that attests to Torcetrapib's compliance with Torcetrapib specifications and serves as a tool for batch-level quality control.
Torcetrapib CoA mostly includes findings from lab analyses of a specific batch. For each Torcetrapib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Torcetrapib may be tested according to a variety of international standards, such as European Pharmacopoeia (Torcetrapib EP), Torcetrapib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Torcetrapib USP).
LOOKING FOR A SUPPLIER?